Introduction: Chemotherapy-induced peripheral neuropathy (CIPN) is a common side effect persisting after completion of neurotoxic chemotherapies. This observational study was designed to evaluate the effectiveness of the dietary supplement OnLife® (patented mixture of specific fatty acids and palmitoylethanolamide) in improving symptoms of CIPN in breast and colon cancer patients. Methods: Improvement of CIPN was evaluated in adult patients, previously treated with (neo)adjuvant paclitaxel- (breast cancer) or oxaliplatin-based (colon cancer) therapies, receiving OnLife® for 3 months after completion of chemotherapy. The primary endpoint was to compare the severity of peripheral sensory neuropathy (PSN) and peripheral motor neuropathy (PMN) before and at the end of OnLife® treatment. Secondary endpoints included the assessment of patient-reported quality of life and CIPN symptoms as assessed by questionnaires. Results: 146 patients (n = 75 breast cancer patients and n = 71 colon cancer patients) qualified for analysis; 31.1% and 37.5% of breast cancer patients had an improvement of PSN and PMN, respectively. In colon cancer patients, PSN and PMN improved in 16.9% and 20.0% of patients, respectively. According to patient-reported outcomes, 45.9% and 37.5% of patients with paclitaxel-induced PSN and PMN, and 23.9% and 22.0% of patients with oxaliplatin-induced PSN and PMN experienced a reduction of CIPN symptoms, respectively. Conclusion: OnLife® treatment confirmed to be beneficial in reducing CIPN severity and in limiting the progression of neuropathy, more markedly in paclitaxel-treated patients and also in patients with oxaliplatin-induced CIPN.
Oncol Res Treat

中文翻译：

---

改善（新）辅助治疗结束后乳腺癌或结肠癌患者化疗引起的周围神经病变：STEFANO 观察性研究的结果

简介：化疗引起的周围神经病变 (CIPN) 是完成神经毒性化疗后持续存在的常见副作用。这项观察性研究旨在评估膳食补充剂 OnLife®（特定脂肪酸和棕榈酰乙醇酰胺的专利混合物）在改善乳腺癌和结肠癌患者 CIPN 症状方面的有效性。方法：在先前接受过（新）辅助紫杉醇（乳腺癌）或奥沙利铂（结肠癌）治疗、化疗完成后接受 OnLife® 3 个月的成年患者中评估了 CIPN 的改善。主要终点是比较 OnLife® 治疗前后周围感觉神经病变 (PSN) 和周围运动神经病变 (PMN) 的严重程度。次要终点包括通过问卷评估患者报告的生活质量和 CIPN 症状。结果： 146 名患者（n = 75 名乳腺癌患者和n= 71 名结肠癌患者）有资格进行分析；分别有 31.1% 和 37.5% 的乳腺癌患者 PSN 和 PMN 有所改善。在结肠癌患者中，PSN 和 PMN 分别在 16.9% 和 20.0% 的患者中得到改善。根据患者报告的结果，45.9% 和 37.5% 的紫杉醇诱导的 PSN 和 PMN 患者以及 23.9% 和 22.0% 的奥沙利铂诱导的 PSN 和 PMN 患者经历了 CIPN 症状的减轻。结论： OnLife® 治疗证实有利于降低 CIPN 严重程度和限制神经病变的进展，在紫杉醇治疗的患者和奥沙利铂诱导的 CIPN 患者中更为显着。
Oncol Res Treat